We are live on
!
Find out more
EFM
E Fund Management Portfolio holdings
AUM
$3.37B
This Fund
S&P 500
This Quarter
Est. Return
-7.89%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
-$29.7M
(-2.7%)
Cap. Flow
+$110M
Cap. Flow
% of AUM
10.28%
Top 10 Holdings %
Top 10 Hldgs %
55.73%
Holding
349
New
26
Increased
163
Reduced
134
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSMC
TSM
|
+$35.5M |
| 2 |
Grab
GRAB
|
+$33.3M |
| 3 |
Qualcomm
QCOM
|
+$25.7M |
| 4 |
Advanced Micro Devices
AMD
|
+$21.8M |
| 5 |
Sea Limited
SE
|
+$18.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mercado Libre
MELI
|
+$26.6M |
| 2 |
Meta Platforms (Facebook)
META
|
+$16M |
| 3 |
DIDI
DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share
DIDI
|
+$6.5M |
| 4 |
NBP
NovaBridge Biosciences American Depositary Shares
NBP
|
+$2.35M |
| 5 |
ProShares Ultra Gold
UGL
|
+$1.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 34.29% |
| 2 | Technology | 26.19% |
| 3 | Communication Services | 11.91% |
| 4 | Healthcare | 11.24% |
| 5 | Real Estate | 7.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
DexCom
DXCM
$29.2B
| $496K | 0.05% |
6,156
+284
| +5% | +$24.1K |
|
127
Palo Alto Networks
PANW
$284B
| $490K | 0.05% |
5,988
+282
| +5% | +$24.4K |
|
|
APLS
128
DELISTED
Apellis Pharmaceuticals
APLS
| $482K | 0.04% |
7,050
-3,601
| -34% | -$213K |
|
129
Illumina
ILMN
$27.9B
| $481K | 0.04% |
2,592
+233
| +10% | +$46.1K |
|
|
SWTX
130
DELISTED
SpringWorks Therapeutics
SWTX
| $479K | 0.04% |
16,803
-3,228
| -16% | -$92.5K |
|
|
GBT
131
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $479K | 0.04% |
7,030
-12,319
| -64% | -$679K |
|
132
Biohaven
BHVN
$2.24B
| $478K | 0.04% |
+3,233
| New | +$23.5K |
|
|
CCXI
133
DELISTED
ChemoCentryx, Inc.
CCXI
| $478K | 0.04% |
9,252
-8,228
| -47% | -$340K |
|
134
Neurocrine Biosciences
NBIX
$17.4B
| $475K | 0.04% |
4,473
-170
| -4% | -$17.2K |
|
135
CRISPR Therapeutics
CRSP
$4.63B
| $465K | 0.04% |
7,113
+245
| +4% | +$17.8K |
|
136
Cintas
CTAS
$80.7B
| $465K | 0.04% |
4,788
+200
| +4% | +$20.4K |
|
137
Fidelity National Information Services
FIS
$21.8B
| $464K | 0.04% |
6,146
-283
| -4% | -$26.4K |
|
138
Kraft Heinz
KHC
$30.7B
| $463K | 0.04% |
13,883
+795
| +6% | +$29.5K |
|
|
ISEE
139
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $460K | 0.04% |
25,624
-14,577
| -36% | -$191K |
|
140
Abbott
ABT
$177B
| $459K | 0.04% |
4,748
+363
| +8% | +$38.7K |
|
141
Danaher
DHR
$142B
| $458K | 0.04% |
2,001
+108
| +6% | +$26.4K |
|
142
Halozyme
HALO
$9.14B
| $455K | 0.04% |
11,505
+1,505
| +15% | +$66.5K |
|
143
Ionis Pharmaceuticals
IONS
$8.75B
| $450K | 0.04% |
10,170
-2,427
| -19% | -$102K |
|
144
Ironwood Pharmaceuticals
IRWD
$634M
| $449K | 0.04% |
43,304
+6,039
| +16% | +$68.5K |
|
145
Acadia Pharmaceuticals
ACAD
$4.3B
| $448K | 0.04% |
27,407
+1,786
| +7% | +$28.9K |
|
146
BioCryst Pharmaceuticals
BCRX
$2.32B
| $446K | 0.04% |
35,417
-8,991
| -20% | -$116K |
|
147
PTC Therapeutics
PTCT
$6.47B
| $446K | 0.04% |
8,881
-4,672
| -34% | -$229K |
|
148
United Therapeutics
UTHR
$22.5B
| $446K | 0.04% |
2,131
+146
| +7% | +$32.6K |
|
|
HZNP
149
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $446K | 0.04% |
7,207
+2,081
| +41% | +$145K |
|
150
Sarepta Therapeutics
SRPT
$1.78B
| $445K | 0.04% |
4,022
-2,311
| -36% | -$233K |
|
Similar funds
VFCM
DFO
DIA
5NCM
TAM
CS
OAM
QCG
E Fund Management's Q3 2022 Portfolio in Review
As of Q3 2022, E Fund Management held 349 positions worth $1.07B, down 2.7% from $1.1B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
E Fund Management deployed $110M of net new capital in Q3 2022, opening 26 new positions and adding to 163 existing holdings. Its largest new stake was TSMC: 430,000 shares worth $29.5M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 34% of assets, down from 36% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Mercado Libre, an estimated $26.6M trimmed.
- E Fund Management's largest Q3 2022 buy was TSMC: 430,000 shares worth $29.5M.
- E Fund Management added most to Grab in Q3 2022, an estimated $33.3M increase.
- E Fund Management's biggest Q3 2022 reduction was Mercado Libre, cutting an estimated $26.6M.
- E Fund Management fully exited DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share in Q3 2022, selling an estimated $6.5M.
- E Fund Management's ten largest holdings make up 56% of its $1.07B portfolio in Q3 2022.
- E Fund Management opened 26 new positions and closed 15 in Q3 2022.
- E Fund Management's portfolio value fell 2.7% quarter-over-quarter to $1.07B.
Based on E Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.